RANCHO CORDOVA, Calif.,
Oct. 31, 2019 /PRNewswire/
-- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market
leader in automated cell processing for regenerative medicine,
today announced that the company will change its name to
ThermoGenesis Holdings, Inc. ("ThermoGenesis") in order to better
reflect its new strategic focus on becoming a key solution provider
for cell manufacturing tools and services in the cell and gene
therapy markets. In conjunction with the name change, the company
will begin trading under the new Nasdaq ticker symbol, THMO,
effective Friday, November 1, 2019.
In addition, the company's common stock will trade under a new
CUSIP number, 88362L100, beginning on Friday, November 1, 2019.
ThermoGenesis® has been a well-respected brand for
automated cell separation and cryostorage technologies in the stem
cell and cord blood industry for nearly three decades. In recent
years, the company has successfully launched a series of new
devices, including the CAR-TXpress™ cellular processing platform.
Recognizing the potential of its proprietary technologies, the
company is committed to further expanding the development of tools
and services in the global cell and gene therapy market. The
company has also decided to terminate its current clinical programs
in the regenerative medicine field in order to focus exclusively on
becoming a preferred solution provider for the global cell and gene
therapy market. In doing so, the company has most recently entered
a definitive agreement with HealthBanks Biotech (USA) to form a joint venture named ImmuneCyte
Life Sciences Inc. to initiate immune cell banking services in the
U.S. using the company's proprietary CART-Xpress
platform.
"ThermoGenesis will continue to take advantage of its
proprietary technology in the automated cell processing field and
focus on developing the next generation of CMO/CDMO services," said
Dr. Chris Xu, Chairman and Chief
Executive Officer of the company. "Our name and ticker change
reflect the company's streamlined business focus toward addressing
critical unmet manufacturing needs in the global cell and gene
therapy market.
"Since its inception in 1986, the company has developed and
commercialized novel cell processing systems and devices that have
provided global researchers, biomanufacturing organizations and
clinicians with highly efficient cell processing devices that have
helped them to deliver better outcomes in various applications in
the cell and gene therapy field," said Phil
Coelho, the company's original Founder and Chief Technology
Officer. "Our present focus will allow us to continue to be at the
forefront to help drive future development of CAR-T cell
therapeutics and other cell and gene therapy products and make them
more accessible to the patients."
About ThermoGenesis Holdings, Inc.
ThermoGenesis
Holdings, Inc., formerly known as Cesca Therapeutics
Inc., develops, commercializes and markets a range of
automated technologies for CAR-T and other cell-based therapies.
The company currently markets a full suite of solutions for
automated clinical biobanking, point-of-care applications, and
automation for immuno-oncology, including its semi-automated,
functionally closed CAR-TXpress™ platform, which streamlines
the manufacturing process for the emerging CAR-T immunotherapy
market. For more information about ThermoGenesis,
please visit: www.cescatherapeutics.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula Schwartz, Rx
Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-change-name-and-ticker-symbol-to-reflect-new-strategic-focus-300948861.html
SOURCE Cesca Therapeutics Inc.